Focus. Together. For patients and society.
Partnering for success
Ipsen Way of Being
Guided by patient outcomes
WHO WE ARE
As a mid-sized global biopharmaceutical company, Ipsen improves people’s lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.
WHAT WE DO
Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to the communities we serve.
Learn more
Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.
Ipsen News
Find out what’s been going on at Ipsen – discover the latest news, trending stories, and updates on our company.
– 15 November 2024
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with…
– 10 June 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…
– 05 June 2024
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary…
– 02 May 2024
Ipsen appoints Keira Driansky as EVP, President of North America
– 13 February 2024
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by…
– 14 November 2023
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late…
– 16 August 2023
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with…
– 14 June 2023
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen…
– 13 June 2023
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
How Ipsen helps
Ipsen focuses on three key therapeutic areas, leveraging our expertise to help people living with unmet medical needs.
Oncology
With over 35 years of oncology experience, our growing portfolio is focused on difficult-to-treat cancers: pancreatic cancer, follicular lymphoma, epithelioid sarcoma, as well as gastrointestinal and pancreatic neuroendocrine tumors and carcinoid syndrome.
Rare Disease
Our focus is on rare growth disorders and rare liver diseases: Alagille Syndrome, biliary atresia, primary familial intrahepatic cholestasis, primary biliary cholangitis, primary sclerosing cholangitis and fibrodysplasia ossificans progressiva.
Neuroscience
Ipsen brings 30 years of clinical experience to advancing the understanding of neurological conditions such as spasticity and cervical dystonia. We are a global leader in the research, development, manufacturing, and commercialization of neurotoxins.
